[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Halothane.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Halothane.]
[L04AA27, fingolimod, The metabolism of Fingolimod can be decreased when combined with Halothane.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Halothane.]
[J01EC02, sulfadiazine, The metabolism of Halothane can be decreased when combined with Sulfadiazine.]
[S01AB01, sulfamethizole, The metabolism of Halothane can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The metabolism of Halothane can be decreased when combined with Sulfamethoxazole.]
[J01EC03, sulfamoxole, The metabolism of Halothane can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Halothane can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Halothane can be decreased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The metabolism of Halothane can be decreased when combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Sulindac is combined with Halothane.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Halothane.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Halothane is combined with Sulthiame.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Halothane.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Halothane is combined with Azapropazone.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Halothane.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Halothane.]
[L01CB02, teniposide, The metabolism of Halothane can be decreased when combined with Teniposide.]
[R03CC03, terbutaline, The risk or severity of hypertension can be increased when Terbutaline is combined with Halothane.]
[G03BA03, testosterone, The metabolism of Halothane can be decreased when combined with Testosterone.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Halothane is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Halothane is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Halothane.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Halothane.]
[L04AX02, thalidomide, Halothane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Halothane.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Halothane.]
[L01AC01, thiotepa, The metabolism of Halothane can be decreased when combined with Thiotepa.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Halothane.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Halothane is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Thioridazine is combined with Halothane.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Halothane is combined with Thiothixene.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Halothane is combined with Moxisylyte.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Halothane is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Halothane can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Halothane is combined with Tilidine.]
[S01ED01, timolol, Halothane may decrease the antihypertensive activities of Timolol.]
[A10BB05, tolazamide, The metabolism of Halothane can be decreased when combined with Tolazamide.]
[M02AX02, tolazoline, Halothane may decrease the antihypertensive activities of Tolazoline.]
[V04CA01, tolbutamide, The metabolism of Halothane can be decreased when combined with Tolbutamide.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Halothane.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Halothane is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of CNS depression can be increased when Halothane is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Halothane is combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of adverse effects can be increased when Halothane is combined with Trazodone.]
[L01XF01, tretinoin, The metabolism of Halothane can be decreased when combined with Tretinoin.]
[C03DB02, triamterene, The risk or severity of adverse effects can be increased when Triamterene is combined with Halothane.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Halothane.]
[C03AA06, trichlormethiazide, Halothane may decrease the antihypertensive activities of Trichlormethiazide.]
[A03AB12, mepenzolate, Halothane may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Halothane.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Halothane is combined with Trifluperidol.]
[N05AA05, triflupromazine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Halothane may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Halothane is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Halothane.]
[C02BA01, trimethaphan, Halothane may decrease the antihypertensive activities of Trimethaphan.]
[J01EA01, trimethoprim, The metabolism of Halothane can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, The risk or severity of adverse effects can be increased when Trimipramine is combined with Halothane.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Halothane.]
[A03BB01, butylscopolamine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Halothane is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Halothane.]
[C09CA09, azilsartan medoxomil, Halothane may decrease the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Halothane is combined with Tubocurarine.]
[J05AG05, rilpivirine, The metabolism of Halothane can be decreased when combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Halothane is combined with Ezogabine.]
[R03AC18, indacaterol, The risk or severity of hypertension can be increased when Halothane is combined with Indacaterol.]
[B01AC24, ticagrelor, The metabolism of Halothane can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The risk or severity of myocardial depression can be increased when Verapamil is combined with Halothane.]
[N06AX09, viloxazine, The metabolism of Halothane can be decreased when combined with Viloxazine.]
[C04AX07, vincamine, Halothane may decrease the antihypertensive activities of Vincamine.]
[B01AA03, warfarin, The metabolism of Halothane can be increased when combined with Warfarin.]
[N01AX15, xenon, The therapeutic efficacy of Xenon can be increased when used in combination with Halothane.]
[C03BA10, xipamide, Halothane may decrease the antihypertensive activities of Xipamide.]
[J05AF01, zidovudine, The metabolism of Halothane can be decreased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Halothane is combined with Zuclopenthixol.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Halothane is combined with Levetiracetam.]
[L01EC01, vemurafenib, The metabolism of Halothane can be decreased when combined with Vemurafenib.]
[R03DC01, zafirlukast, The metabolism of Halothane can be decreased when combined with Zafirlukast.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Halothane is combined with Ziprasidone.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Halothane.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Halothane.]
[G04BD07, tolterodine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[C07AB03, atenolol, Halothane may decrease the antihypertensive activities of Atenolol.]
[J02AC03, voriconazole, The metabolism of Halothane can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Halothane is combined with Atracurium.]
[S01FA01, atropine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Halothane.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Halothane.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Halothane.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Halothane is combined with Lorcaserin.]
[G04BD12, mirabegron, The risk or severity of hypertension can be increased when Halothane is combined with Mirabegron.]
[L02BB04, enzalutamide, The serum concentration of Halothane can be decreased when it is combined with Enzalutamide.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Halothane is combined with Octopamine.]
[L01EX05, regorafenib, The metabolism of Halothane can be decreased when combined with Regorafenib.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Halothane.]
[J05AE04, nelfinavir, The metabolism of Halothane can be decreased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Halothane.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Halothane is combined with Rasagiline.]
[C08CA13, lercanidipine, Halothane may decrease the antihypertensive activities of Lercanidipine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Halothane is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Halothane.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Halothane.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Halothane.]
[R06AC06, thonzylamine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Halothane may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AB02, chloroform, The therapeutic efficacy of Chloroform can be increased when used in combination with Halothane.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Halothane is combined with Diethyl ether.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Halothane.]
[G04BE03, sildenafil, The metabolism of Halothane can be decreased when combined with Sildenafil.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Halothane.]
[C03AA01, bendroflumethiazide, Halothane may decrease the antihypertensive activities of Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Halothane is combined with Pomalidomide.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Halothane.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Halothane is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Halothane is combined with Benperidol.]
[A10BK02, canagliflozin, The risk or severity of adverse effects can be increased when Halothane is combined with Canagliflozin.]
[M04AB03, benzbromarone, The metabolism of Halothane can be decreased when combined with Benzbromarone.]
[A06AX06, tegaserod, The metabolism of Halothane can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Benzocaine is combined with Halothane.]
[M01AH01, celecoxib, The risk or severity of hypertension can be increased when Celecoxib is combined with Halothane.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Halothane.]
[N04AC01, benztropine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Halothane can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Halothane is combined with Benzydamine.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Halothane is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Halothane is combined with Levomilnacipran.]
[C08EA02, bepridil, Halothane may decrease the antihypertensive activities of Bepridil.]
[C02KX05, riociguat, Halothane may decrease the antihypertensive activities of Riociguat.]
[C02KX04, macitentan, Halothane may decrease the antihypertensive activities of Macitentan.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Halothane is combined with Vortioxetine.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Halothane is combined with Eslicarbazepine.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Halothane.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Halothane.]
[C01CA27, droxidopa, The risk or severity of hypertension can be increased when Halothane is combined with Droxidopa.]
[C07AB04, acebutolol, Halothane may decrease the antihypertensive activities of Acebutolol.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Halothane is combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Halothane can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Halothane can be increased when combined with Apremilast.]
[S03BA03, betamethasone, The metabolism of Halothane can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, Halothane may decrease the antihypertensive activities of Betaxolol.]
[V03AB34, fomepizole, The metabolism of Halothane can be decreased when combined with Fomepizole.]
[C02CC01, bethanidine, Halothane may decrease the antihypertensive activities of Bethanidine.]
[L04AC11, siltuximab, The metabolism of Halothane can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Halothane can be decreased when combined with Ceritinib.]
[A03BA03, hyoscyamine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Halothane.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Halothane is combined with Alfaxalone.]
[A10BK03, empagliflozin, The risk or severity of adverse effects can be increased when Halothane is combined with Empagliflozin.]
[R03AC19, olodaterol, The risk or severity of hypertension can be increased when Halothane is combined with Olodaterol.]
[D11AA01, glycopyrronium, Halothane may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Halothane may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[J01XA05, oritavancin, The metabolism of Halothane can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Halothane is combined with Acepromazine.]
[N04AA02, biperiden, Halothane may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Halothane.]
[B01AA01, dicumarol, The metabolism of Halothane can be decreased when combined with Dicoumarol.]
[N06AX11, mirtazapine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Halothane can be increased when combined with Secukinumab.]
[N02BE01, acetaminophen, Halothane may increase the hepatotoxic activities of Acetaminophen.]
[A03AA09, difemerine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Halothane.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Halothane is combined with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Halothane is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Halothane is combined with Cariprazine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Halothane is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Halothane is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Halothane.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Acetophenazine is combined with Halothane.]
[A02BC03, lansoprazole, The metabolism of Halothane can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Halothane.]
[J02AC05, isavuconazole, The metabolism of Halothane can be decreased when combined with Isavuconazole.]
[B01AC27, selexipag, Halothane may decrease the antihypertensive activities of Selexipag.]
[A10BB31, acetohexamide, The metabolism of Halothane can be decreased when combined with Acetohexamide.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be decreased when combined with Halothane.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Halothane is combined with Aprobarbital.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Halothane is combined with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Halothane is combined with Brivaracetam.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Halothane is combined with Bromazepam.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Halothane is combined with Bromocriptine.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Halothane is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Halothane.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Halothane is combined with Amineptine.]
[C08CA01, amlodipine, Halothane may decrease the antihypertensive activities of Amlodipine.]
[N01AH05, anileridine, The therapeutic efficacy of Halothane can be increased when used in combination with Anileridine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Halothane is combined with Aniracetam.]
[C03CA02, bumetanide, The risk or severity of adverse effects can be increased when Bumetanide is combined with Halothane.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Halothane.]
[C07AA19, bupranolol, Halothane may decrease the antihypertensive activities of Bupranolol.]
[N07BC01, buprenorphine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Halothane.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Halothane is combined with Arsenic trioxide.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Halothane.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Halothane.]
[S01GX07, azelastine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Halothane can be decreased when combined with Rucaparib.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Balsalazide is combined with Halothane.]
[R03CC12, bambuterol, The risk or severity of hypertension can be increased when Halothane is combined with Bambuterol.]
[N02BF02, pregabalin, The therapeutic efficacy of Halothane can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Halothane is combined with Beclamide.]
[C09AA07, benazepril, Halothane may decrease the antihypertensive activities of Benazepril.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Halothane.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Halothane is combined with Linezolid.]
[L04AB02, infliximab, The metabolism of Halothane can be increased when combined with Infliximab.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Halothane is combined with Safinamide.]
[J01MA23, delafloxacin, The metabolism of Halothane can be increased when combined with Delafloxacin.]
[D01AC10, bifonazole, The metabolism of Halothane can be decreased when combined with Bifonazole.]
[L01BC06, capecitabine, The metabolism of Halothane can be decreased when combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Halothane.]
[C07AB07, bisoprolol, Halothane may decrease the antihypertensive activities of Bisoprolol.]
[R03AC17, bitolterol, The risk or severity of hypertension can be increased when Bitolterol is combined with Halothane.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Halothane.]
[C07AA17, bopindolol, Halothane may increase the cardiodepressant activities of Bopindolol.]
[N04AA11, bornaprine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Halothane is combined with Nesiritide.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Halothane is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Halothane is combined with Brotizolam.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Halothane is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Halothane is combined with Bumadizone.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Halothane is combined with Butobarbital.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Halothane is combined with Butriptyline.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Halothane is combined with Vinylbital.]
[C09AA01, captopril, Halothane may decrease the antihypertensive activities of Captopril.]
[L02BB05, apalutamide, The metabolism of Halothane can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Carbamazepine is combined with Halothane.]
[A03AA03, camylofine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Halothane.]
[C07AG02, carvedilol, The metabolism of Halothane can be decreased when combined with Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Halothane.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Halothane.]
[B02BX08, avatrombopag, The metabolism of Halothane can be increased when combined with Avatrombopag.]
[C07AB08, celiprolol, Halothane may decrease the antihypertensive activities of Celiprolol.]
[L01XX62, ivosidenib, The metabolism of Halothane can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Halothane can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Halothane.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Halothane.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Halothane is combined with Carbromal.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Halothane.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Halothane is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Halothane is combined with Lornoxicam.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Halothane.]
[R03BB08, revefenacin, Halothane may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L04AA39, emapalumab, The metabolism of Halothane can be increased when combined with Emapalumab.]
[C09AA08, cilazapril, Halothane may decrease the antihypertensive activities of Cilazapril.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Halothane is combined with Cinitapride.]
[P02BX04, triclabendazole, The metabolism of Halothane can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Halothane.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Halothane is combined with Siponimod.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Halothane.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Halothane is combined with Brexanolone.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Halothane.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Halothane.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Halothane is combined with Cloxazolam.]
[C09CA06, candesartan, Halothane may decrease the antihypertensive activities of Candesartan.]
[L04AB01, etanercept, The metabolism of Halothane can be increased when combined with Etanercept.]
[L01EM03, alpelisib, The serum concentration of Halothane can be decreased when it is combined with Alpelisib.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Halothane is combined with Cyamemazine.]
[C03BX03, cicletanine, Halothane may decrease the antihypertensive activities of Cicletanine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Halothane.]
[N07XX11, pitolisant, The serum concentration of Halothane can be decreased when it is combined with Pitolisant.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Halothane.]
[C03AA09, cyclothiazide, Halothane may decrease the antihypertensive activities of Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Halothane is combined with Yohimbine.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Halothane.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Halothane.]
[G03AC09, desogestrel, The metabolism of Halothane can be decreased when combined with Desogestrel.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Halothane.]
[N03AX25, cenobamate, The serum concentration of Halothane can be decreased when it is combined with Cenobamate.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Halothane.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Halothane is combined with Dezocine.]
[L01EX18, avapritinib, The metabolism of Halothane can be decreased when combined with Avapritinib.]
[N05CM21, lemborexant, The serum concentration of Halothane can be decreased when it is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Halothane is combined with Lumateperone.]
[M01AX21, diacetylrhein, The metabolism of Halothane can be decreased when combined with Diacerein.]
[H02CA02, osilodrostat, The metabolism of Osilodrostat can be decreased when combined with Halothane.]
[J05AE05, amprenavir, The metabolism of Halothane can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Halothane.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Dutasteride is combined with Halothane.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Halothane is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Halothane.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Halothane is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Halothane is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Halothane.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Rofecoxib is combined with Halothane.]
[L01XF03, bexarotene, The metabolism of Halothane can be decreased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Halothane can be decreased when combined with Clevidipine.]
[C01BD07, dronedarone, The risk or severity of hypertension can be increased when Halothane is combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Halothane is combined with Valpromide.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Halothane.]
[C02AA06, methoserpidine, Halothane may decrease the antihypertensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Halothane.]
[A03AA08, dihexyverine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Halothane is combined with Opicapone.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Halothane is combined with Dopexamine.]
[P01BE01, artemisinin, The metabolism of Artemisinin can be decreased when combined with Halothane.]
[G04BD09, trospium, Halothane may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Halothane is combined with Droxicam.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Halothane is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Halothane is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Halothane is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Halothane is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Halothane.]
[C08CA17, levamlodipine, Halothane may decrease the antihypertensive activities of Levamlodipine.]
[P01BB01, proguanil, The metabolism of Halothane can be decreased when combined with Proguanil.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Halothane is combined with Remimazolam.]
[L04AC19, satralizumab, The serum concentration of Halothane can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Halothane is combined with Oliceridine.]
[L01EX23, pralsetinib, The metabolism of Halothane can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, Halothane may decrease the antihypertensive activities of Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Halothane.]
[N05AA01, chlorpromazine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.]
[A10BB02, chlorpropamide, The metabolism of Halothane can be decreased when combined with Chlorpropamide.]
[N05AF03, chlorprothixene, Halothane may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, Halothane may decrease the antihypertensive activities of Chlorthalidone.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Halothane.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Halothane is combined with Etifoxine.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Halothane is combined with Ethenzamide.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Halothane is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Halothane is combined with Ethyl loflazepate.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Etodolac is combined with Halothane.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Halothane is combined with Etofenamate.]
[A16AX20, lonafarnib, The metabolism of Lonafarnib can be decreased when combined with Halothane.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Halothane is combined with Naxitamab.]
[P03AX07, abametapir, The serum concentration of Halothane can be increased when it is combined with Abametapir.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Halothane is combined with Vericiguat.]
[L01EX21, tepotinib, The metabolism of Halothane can be decreased when combined with Tepotinib.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Halothane is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Halothane.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Halothane is combined with Fenbufen.]
[C01CA19, fenoldopam, Halothane may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Halothane is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Halothane is combined with Finasteride.]
[R03CC15, formoterol, Halothane may increase the arrhythmogenic activities of Formoterol.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Halothane is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The metabolism of Halothane can be increased when combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Halothane may decrease the antihypertensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The metabolism of Halothane can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Halothane.]
[N07CA02, cinnarizine, The metabolism of Halothane can be decreased when combined with Cinnarizine.]
[L01XX73, sotorasib, The serum concentration of Halothane can be decreased when it is combined with Sotorasib.]
[L01XA01, cisplatin, The metabolism of Halothane can be decreased when combined with Cisplatin.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Halothane is combined with Citalopram.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Halothane.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Halothane.]
[A10BB12, glimepiride, The metabolism of Halothane can be decreased when combined with Glimepiride.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be decreased when combined with Halothane.]
[R03CC13, clenbuterol, The risk or severity of hypertension can be increased when Halothane is combined with Clenbuterol.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when Halothane is combined with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Halothane can be decreased when combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Halothane.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Halothane.]
[C10AB01, clofibrate, The metabolism of Halothane can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Halothane can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Halothane.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Halothane is combined with Clomipramine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Clonazepam is combined with Halothane.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Halothane.]
[C01EB24, mavacamten, The serum concentration of Halothane can be decreased when it is combined with Mavacamten.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Halothane is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Halothane is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Halothane.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Halothane.]
[N05AH02, clozapine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Clozapine.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Halothane.]
[H01AC08, somatrogon, The metabolism of Halothane can be increased when combined with Somatrogon.]
[S02DA02, cocaine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Halothane may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Halothane can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Halothane is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Halothane.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Halothane.]
[A03AB10, hexocyclium, Halothane may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Halothane may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[L04AA13, leflunomide, The metabolism of Halothane can be decreased when combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Halothane is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Halothane is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Halothane is combined with Ifenprodil.]
[A10BX03, nateglinide, The metabolism of Halothane can be decreased when combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Halothane is combined with Imidazole salicylate.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Halothane is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Halothane.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Valdecoxib is combined with Halothane.]
[A03AX10, isometheptene, The risk or severity of hypertension can be increased when Halothane is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Halothane.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Halothane is combined with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Halothane can be decreased when combined with Itraconazole.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Halothane is combined with Ketazolam.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Halothane is combined with Kebuzone.]
[L01EA01, imatinib, The metabolism of Halothane can be decreased when combined with Imatinib.]
[C08CA09, lacidipine, Halothane may increase the hypotensive activities of Lacidipine.]
[N03AX09, lamotrigine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[N07BC04, lofexidine, The therapeutic efficacy of Halothane can be increased when used in combination with Lofexidine.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Halothane is combined with Lonazolac.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Halothane is combined with Lormetazepam.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Halothane is combined with Loxoprofen.]
[C09AA03, lisinopril, Halothane may decrease the antihypertensive activities of Lisinopril.]
[C08CA11, manidipine, The metabolism of Halothane can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Halothane is combined with Medifoxamine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Halothane is combined with Mefenorex.]
[C07AA14, mepindolol, Halothane may increase the cardiodepressant activities of Mepindolol.]
[N04AA03, methixene, Halothane may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R03CB02, methoxyphenamine, The risk or severity of hypertension can be increased when Halothane is combined with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Halothane is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Halothane is combined with Cyclobarbital.]
[C03DA04, eplerenone, Halothane may decrease the antihypertensive activities of Eplerenone.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Halothane is combined with Melperone.]
[C03AA07, cyclopenthiazide, Halothane may decrease the antihypertensive activities of Cyclopenthiazide.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Halothane.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Halothane is combined with Minaprine.]
[S01XA18, cyclosporine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Halothane.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Halothane is combined with Moclobemide.]
[N06BA07, modafinil, The metabolism of Halothane can be decreased when combined with Modafinil.]
[R06AX02, cyproheptadine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, Halothane may decrease the antihypertensive activities of Moexipril.]
[C10AA07, rosuvastatin, The metabolism of Halothane can be decreased when combined with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Halothane is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Halothane is combined with Morniflumate.]
[C03XA02, conivaptan, The risk or severity of adverse effects can be increased when Conivaptan is combined with Halothane.]
[C02AC05, moxonidine, Halothane may decrease the antihypertensive activities of Moxonidine.]
[G04BE09, vardenafil, The risk or severity of hypotension can be increased when Vardenafil is combined with Halothane.]
[M01AH05, etoricoxib, The metabolism of Halothane can be decreased when combined with Etoricoxib.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Halothane is combined with Dantrolene.]
[J04BA02, dapsone, The metabolism of Halothane can be decreased when combined with Dapsone.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Halothane is combined with Deanol.]
[C02CC04, debrisoquin, Halothane may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Halothane.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Nabumetone is combined with Halothane.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Halothane is combined with Nordazepam.]
[C07AB12, nebivolol, Halothane may decrease the antihypertensive activities of Nebivolol.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Halothane is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Halothane is combined with Niaprazine.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Halothane.]
[L02BB02, nilutamide, The metabolism of Halothane can be decreased when combined with Nilutamide.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Halothane.]
[C01CA23, theodrenaline, The risk or severity of hypertension can be increased when Halothane is combined with Theodrenaline.]
[M03AC11, cisatracurium, Halothane may increase the neuromuscular blocking activities of Cisatracurium.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Halothane is combined with Norfenefrine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Halothane is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Halothane is combined with Escitalopram.]
[G04BD08, solifenacin, Halothane may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Halothane is combined with Olsalazine.]
[N06AA01, desipramine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Halothane.]
[C09XA02, aliskiren, Halothane may decrease the antihypertensive activities of Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Oxaprozin is combined with Halothane.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Halothane.]
[S03BA01, dexamethasone, The metabolism of Halothane can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Halothane is combined with Oxiracetam.]
[N04AA08, dexetimide, Halothane may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Halothane may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Halothane can be decreased when combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Halothane can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Halothane.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Halothane.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Halothane.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Halothane is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Halothane is combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Halothane can be decreased when combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Halothane is combined with Diamorphine.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Halothane.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Phenacemide is combined with Halothane.]
[V03AH01, diazoxide, Halothane may decrease the antihypertensive activities of Diazoxide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Halothane.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Halothane is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Halothane.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Diclofenamide is combined with Halothane.]
[S01BC03, diclofenac, The metabolism of Halothane can be decreased when combined with Diclofenac.]
[A03AA07, dicyclomine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[C02DG01, pinacidil, Halothane may decrease the antihypertensive activities of Pinacidil.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Halothane is combined with Pipamperone.]
[A03AB14, pipenzolate, Halothane may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[R03CC07, pirbuterol, The risk or severity of hypertension can be increased when Halothane is combined with Pirbuterol.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Diethylpropion is combined with Halothane.]
[L02AA01, diethylstilbestrol, The metabolism of Halothane can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, Halothane may decrease the antihypertensive activities of Isradipine.]
[A03AB11, poldine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Diflunisal is combined with Halothane.]
[C02DB01, dihydralazine, Halothane may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, The risk or severity of hypertension can be increased when Halothane is combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Halothane.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Halothane.]
[J05AE08, atazanavir, The metabolism of Halothane can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, Halothane may decrease the antihypertensive activities of Treprostinil.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Halothane is combined with Pramocaine.]
[C08DB01, diltiazem, Halothane may decrease the antihypertensive activities of Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Halothane.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Halothane is combined with Pridinol.]
[R06AB03, dimethindene, Halothane may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, The risk or severity of hypertension can be increased when Halothane is combined with Procaterol.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Halothane.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Halothane is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Halothane is combined with Proglumetacin.]
[C05CA03, diosmin, The metabolism of Halothane can be decreased when combined with Diosmin.]
[R06AA02, diphenhydramine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Halothane.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Halothane is combined with Quazepam.]
[C09AA06, quinapril, Halothane may decrease the antihypertensive activities of Quinapril.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Halothane.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may increase the hypertensive activities of Halothane.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Halothane is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Cisapride is combined with Halothane.]
[C09AA05, ramipril, Halothane may decrease the antihypertensive activities of Ramipril.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Halothane.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Halothane is combined with Reproterol.]
[C01BA03, disopyramide, Halothane may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[P03AA04, disulfiram, The metabolism of Halothane can be decreased when combined with Disulfiram.]
[S02AA12, rifamycin SV, The metabolism of Halothane can be decreased when combined with Rifamycin.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Halothane.]
[N05AX08, risperidone, Halothane may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Halothane is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Halothane.]
[L01XG01, bortezomib, The metabolism of Halothane can be decreased when combined with Bortezomib.]
[G04BE08, tadalafil, Halothane may decrease the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Ketorolac is combined with Halothane.]
[C02KX02, ambrisentan, Halothane may decrease the antihypertensive activities of Ambrisentan.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Halothane is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of hypertension can be increased when Salmeterol is combined with Halothane.]
[C01CA07, dobutamine, The risk or severity of hypertension can be increased when Dobutamine is combined with Halothane.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Halothane.]
[C01CA04, dopamine, Halothane may increase the arrhythmogenic activities of Dopamine.]
[N06AA16, dothiepin, The metabolism of Dosulepin can be decreased when combined with Halothane.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Halothane.]
[N06AA12, doxepin, Halothane may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Halothane.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Halothane is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Halothane is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Halothane.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Halothane is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Halothane can be increased when combined with Simvastatin.]
[C09AA11, spirapril, Halothane may decrease the antihypertensive activities of Spirapril.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Halothane is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Halothane.]
[C07AB13, talinolol, Halothane may decrease the antihypertensive activities of Talinolol.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Tenoxicam is combined with Halothane.]
[G04CA03, terazosin, Halothane may decrease the antihypertensive activities of Terazosin.]
[D01BA02, terbinafine, The metabolism of Halothane can be decreased when combined with Terbinafine.]
[C07AA16, tertatolol, Halothane may increase the cardiodepressant activities of Tertatolol.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Halothane is combined with Tetryzoline.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Halothane is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Halothane is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Halothane is combined with Thiopropazate.]
[G04BD01, emepronium, Halothane may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Halothane is combined with Tianeptine.]
[C09AA02, enalapril, Halothane may decrease the antihypertensive activities of Enalapril.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Halothane is combined with Tofisopam.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Halothane is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Halothane is combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Halothane.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Halothane.]
[C03CA04, torsemide, The metabolism of Halothane can be decreased when combined with Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Halothane is combined with Tramazoline.]
[C09AA10, trandolapril, Halothane may decrease the antihypertensive activities of Trandolapril.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Halothane is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Halothane is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Halothane is combined with Triclofos.]
[A03AB08, tridihexethyl, Halothane may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Halothane.]
[N04AA12, tropatepine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Halothane is combined with Tulobuterol.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Halothane.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Halothane is combined with Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Halothane is combined with Veralipride.]
[S01FB02, ephedrine, Ephedrine may increase the arrhythmogenic activities of Halothane.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Halothane.]
[N06AX16, venlafaxine, The risk or severity of adverse effects can be increased when Venlafaxine is combined with Halothane.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Halothane is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Halothane is combined with Xylometazoline.]
[C08CA12, mepirodipine, The risk or severity of adverse effects can be increased when Halothane is combined with Barnidipine.]
[S01EA01, epinephrine, Halothane may increase the arrhythmogenic activities of Epinephrine.]
[C09AA15, zofenopril, Halothane may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, Halothane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Halothane is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Zonisamide is combined with Halothane.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Halothane is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Halothane is combined with Zotepine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Halothane.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Iloprost is combined with Halothane.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Halothane.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Halothane is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Halothane.]
[N02CA02, ergotamine, The risk or severity of adverse effects can be increased when Ergotamine is combined with Halothane.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Halothane.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Halothane is combined with Estazolam.]
[G03CA03, estradiol, The metabolism of Halothane can be decreased when combined with Estradiol.]
[J04AK02, ethambutol, The metabolism of Halothane can be decreased when combined with Ethambutol.]
[C10AA04, fluvastatin, The metabolism of Halothane can be increased when combined with Fluvastatin.]
[C01CA15, gepefrine, The risk or severity of hypertension can be increased when Halothane is combined with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Halothane.]
[L02AA03, ethinyl estradiol, The metabolism of Halothane can be decreased when combined with Ethinylestradiol.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Amifostine is combined with Halothane.]
[N04AA05, profenamine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Halothane.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Halothane.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Meloxicam is combined with Halothane.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Halothane is combined with Ethylmorphine.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Halothane is combined with Etilefrine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Halothane.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Halothane is combined with Sertindole.]
[R06AX12, terfenadine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Bupropion is combined with Halothane.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Halothane is combined with Fluvoxamine.]
[C08CA02, felodipine, The metabolism of Halothane can be decreased when combined with Felodipine.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Fenfluramine is combined with Halothane.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Fenoprofen is combined with Halothane.]
[R03CC04, fenoterol, The risk or severity of hypertension can be increased when Halothane is combined with Fenoterol.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Halothane.]
[R03CC02, albuterol, The risk or severity of hypertension can be increased when Salbutamol is combined with Halothane.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Halothane.]
[G04BD02, flavoxate, Halothane may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Halothane can be decreased when combined with Flecainide.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Halothane is combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Halothane can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Halothane is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Halothane is combined with Flunitrazepam.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Halothane is combined with Melitracen.]
[V03AZ01, ethanol, Halothane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, The metabolism of Halothane can be decreased when combined with Floxuridine.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Halothane.]
[N06AB03, fluoxetine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, Halothane may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Halothane.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Halothane.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Flurbiprofen is combined with Halothane.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Halothane is combined with Fluspirilene.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Halothane.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Halothane is combined with Adrafinil.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Halothane is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Halothane is combined with Furazolidone.]
[C03CA01, furosemide, Halothane may decrease the antihypertensive activities of Furosemide.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Halothane is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Halothane is combined with Amisulpride.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Halothane is combined with Gallamine.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Halothane.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Halothane is combined with Bifemelane.]
[C10AB04, gemfibrozil, The metabolism of Halothane can be decreased when combined with Gemfibrozil.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Cabergoline is combined with Halothane.]
[J05AG04, etravirine, The metabolism of Halothane can be decreased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Halothane is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Halothane.]
[A10BB01, glyburide, The metabolism of Halothane can be decreased when combined with Glyburide.]
[A10BB09, gliclazide, The metabolism of Halothane can be decreased when combined with Gliclazide.]
[A10BB07, glipizide, The metabolism of Halothane can be decreased when combined with Glipizide.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Halothane.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Halothane is combined with Glutethimide.]
[A06AX01, glycerin, The metabolism of Halothane can be increased when combined with Glycerin.]
[C05AE01, nitroglycerin, Halothane may decrease the antihypertensive activities of Nitroglycerin.]
[C02CA04, doxazosin, Halothane may decrease the antihypertensive activities of Doxazosin.]
[L01EX02, sorafenib, The metabolism of Halothane can be decreased when combined with Sorafenib.]
[C07AB09, esmolol, Halothane may decrease the antihypertensive activities of Esmolol.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Halothane.]
[C09AA09, fosinopril, Halothane may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Halothane may decrease the antihypertensive activities of Guanethidine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Halothane.]
[N07XX04, sodium oxybate, The risk or severity of adverse effects can be increased when Halothane is combined with Sodium oxybate.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Mefenamic acid is combined with Halothane.]
[N05AH04, quetiapine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Halothane is combined with Iprazochrome.]
[L01CE02, irinotecan, The metabolism of Halothane can be decreased when combined with Irinotecan.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Halothane is combined with Allobarbital.]
[C09CA01, losartan, Halothane may decrease the antihypertensive activities of Losartan.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Halothane.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Halothane.]
[R03CC05, hexoprenaline, The risk or severity of hypertension can be increased when Halothane is combined with Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Halothane can be increased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Nilvadipine can be decreased when combined with Halothane.]
[M02AA26, nimesulide, The risk or severity of hypertension can be increased when Halothane is combined with Nimesulide.]
[C09AA04, perindopril, Halothane may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Halothane may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, Halothane may decrease the antihypertensive activities of Hydrochlorothiazide.]
[R05DA03, hydrocodone, Halothane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The metabolism of Halothane can be increased when combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, Halothane may decrease the antihypertensive activities of Hydroflumethiazide.]
[G04BD06, propiverine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Halothane is combined with Prothipendyl.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Halothane.]
[J04AB04, rifabutin, The metabolism of Halothane can be increased when combined with Rifabutin.]
[C02AC06, rilmenidine, Halothane may decrease the antihypertensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Ibuprofen is combined with Halothane.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Halothane.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Halothane.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Halothane.]
[N06AA02, imipramine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Imipramine.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Halothane is combined with Paclitaxel.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Halothane.]
[C03BA11, indapamide, Halothane may decrease the antihypertensive activities of Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Indomethacin is combined with Halothane.]
[C02CA02, indoramin, Halothane may decrease the antihypertensive activities of Indoramin.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Halothane is combined with Milnacipran.]
[A03AA30, piperidolate, Halothane may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Halothane is combined with Articaine.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Halothane.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Halothane.]
[R06AE01, buclizine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C10AA06, cerivastatin, The metabolism of Halothane can be increased when combined with Cerivastatin.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Alprenolol is combined with Halothane.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Halothane is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Halothane is combined with Iproniazid.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Halothane is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Halothane is combined with Isocarboxazid.]
[P01AX06, atovaquone, The metabolism of Halothane can be decreased when combined with Atovaquone.]
[R03CC06, isoetharine, The risk or severity of hypertension can be increased when Isoetharine is combined with Halothane.]
[C09AA16, imidapril, Halothane may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Halothane.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Halothane.]
[J04AC01, isoniazid, The metabolism of Halothane can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, Halothane may increase the arrhythmogenic activities of Isoprenaline.]
[C05AE02, isosorbide dinitrate, The metabolism of Halothane can be decreased when combined with Isosorbide dinitrate.]
[C04AA01, isoxsuprine, The risk or severity of hypertension can be increased when Halothane is combined with Isoxsuprine.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Halothane.]
[L04AC07, tocilizumab, The metabolism of Halothane can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Halothane is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Halothane is combined with Ketanserin.]
[B01AC22, prasugrel, The metabolism of Prasugrel can be decreased when combined with Halothane.]
[J02AB02, ketoconazole, The metabolism of Halothane can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Ketoprofen is combined with Halothane.]
[L04AA24, abatacept, The metabolism of Halothane can be increased when combined with Abatacept.]
[C01CA22, arbutamine, The risk or severity of hypertension can be increased when Arbutamine is combined with Halothane.]
[N04BC09, rotigotine, Halothane may increase the sedative activities of Rotigotine.]
[C07AG01, labetalol, Halothane may decrease the antihypertensive activities of Labetalol.]
[C02AA05, deserpidine, Halothane may decrease the antihypertensive activities of Deserpidine.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Halothane is combined with Lacosamide.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Halothane is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Halothane.]
[N06BA13, armodafinil, The metabolism of Halothane can be increased when combined with Armodafinil.]
[C03DB01, amiloride, The risk or severity of adverse effects can be increased when Amiloride is combined with Halothane.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Lisuride is combined with Halothane.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Halothane is combined with Lofepramine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Halothane.]
[C10AA02, lovastatin, The metabolism of Halothane can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Halothane.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Halothane.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Halothane can be increased when used in combination with Magnesium sulfate.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Mannitol is combined with Halothane.]
[N06AA21, maprotiline, Halothane may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Halothane.]
[C02BB01, mecamylamine, Halothane may decrease the antihypertensive activities of Mecamylamine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Halothane.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Halothane.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Halothane is combined with Medazepam.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Melatonin is combined with Halothane.]
[N06DX01, memantine, The risk or severity of adverse effects can be increased when Halothane is combined with Memantine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Halothane.]
[C01CA11, mephentermine, The risk or severity of hypertension can be increased when Halothane is combined with Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Halothane.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Halothane.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Mepivacaine is combined with Halothane.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Halothane.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Halothane is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Mesoridazine is combined with Halothane.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Halothane is combined with Paliperidone.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Metaraminol is combined with Halothane.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Halothane.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Halothane.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Halothane is combined with Metamfetamine.]
[A03AB07, methantheline, Halothane may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Halothane is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Halothane is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Halothane.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Methazolamide is combined with Halothane.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Halothane is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Halothane can be decreased when combined with Methimazole.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Halothane.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Halothane.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Halothane is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Methoxamine is combined with Halothane.]
[D05BA02, methoxsalen, The metabolism of Halothane can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Halothane.]
[C03AA08, methyclothiazide, The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Halothane.]
[C02AB01, methyldopa, Halothane may decrease the antihypertensive activities of Methyldopa.]
[V04CG05, methylene blue, The risk or severity of adverse effects can be increased when Halothane is combined with Methylene blue.]
[G02AB01, methylergonovine, The risk or severity of hypertension can be increased when Methylergometrine is combined with Halothane.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Halothane.]
[N06BA04, methylphenidate, Methylphenidate may increase the hypertensive activities of Halothane.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Halothane.]
[G03EK01, methyltestosterone, The metabolism of Methyltestosterone can be decreased when combined with Halothane.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methyprylon is combined with Halothane.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Halothane.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Halothane.]
[C03BA08, metolazone, Halothane may decrease the antihypertensive activities of Metolazone.]
[C07AB02, metoprolol, Halothane may decrease the antihypertensive activities of Metoprolol.]
[P01AB01, metronidazole, The metabolism of Halothane can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The metabolism of Halothane can be decreased when combined with Metyrapone.]
[C01BB02, mexiletine, The metabolism of Halothane can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Halothane is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Halothane can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of hypertension can be increased when Halothane is combined with Aminophenazone.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Halothane.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Midodrine is combined with Halothane.]
[G03XB01, mifepristone, The metabolism of Halothane can be decreased when combined with Mifepristone.]
[C09CA03, valsartan, The metabolism of Halothane can be decreased when combined with Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Halothane.]
[D11AX01, minoxidil, Halothane may decrease the antihypertensive activities of Minoxidil.]
[L01DB07, mitoxantrone, The metabolism of Halothane can be increased when combined with Mitoxantrone.]
[N06BA12, lisdexamfetamine, The risk or severity of hypertension can be increased when Halothane is combined with Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Halothane is combined with Molindone.]
[L03AC01, aldesleukin, The metabolism of Halothane can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, Amiodarone may increase the cardiodepressant activities of Halothane.]
[N06AA09, amitriptyline, Halothane may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.]
[N02AA01, morphine, The therapeutic efficacy of Morphine can be increased when used in combination with Halothane.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Halothane.]
[L04AB05, certolizumab pegol, The metabolism of Halothane can be increased when combined with Certolizumab pegol.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Halothane is combined with Vecuronium.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Halothane.]
[P01BA06, amodiaquine, The metabolism of Halothane can be decreased when combined with Amodiaquine.]
[G03XC01, raloxifene, The metabolism of Halothane can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The serum concentration of Fosphenytoin can be increased when it is combined with Halothane.]
[C07AA12, nadolol, Halothane may decrease the antihypertensive activities of Nadolol.]
[N04BC04, ropinirole, Halothane may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Halothane is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Halothane.]
[L04AC03, anakinra, The metabolism of Halothane can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The risk or severity of hypertension can be increased when Halothane is combined with Naphazoline.]
[N06BA01, amphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Halothane.]
[M02AA12, naproxen, The risk or severity of hypertension can be increased when Naproxen is combined with Halothane.]
[A10BG01, troglitazone, The metabolism of Halothane can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Halothane is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Halothane.]
[L02BG04, letrozole, The metabolism of Halothane can be decreased when combined with Letrozole.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Halothane.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Levosimendan is combined with Halothane.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Halothane is combined with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Halothane.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Halothane is combined with Desvenlafaxine.]
[C09CA07, telmisartan, Halothane may decrease the antihypertensive activities of Telmisartan.]
[C10AD02, niacin, The metabolism of Halothane can be decreased when combined with Niacin.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Halothane is combined with Nialamide.]
[C08CA04, nicardipine, The metabolism of Halothane can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The risk or severity of hypertension can be increased when Nicergoline is combined with Halothane.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Halothane.]
[N07BA01, nicotine, The metabolism of Halothane can be increased when combined with Nicotine.]
[C08CA05, nifedipine, The metabolism of Halothane can be decreased when combined with Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Halothane is combined with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Halothane is combined with Amyl Nitrite.]
[C08CA06, nimodipine, Halothane may decrease the antihypertensive activities of Nimodipine.]
[C08CA07, nisoldipine, Halothane may decrease the antihypertensive activities of Nisoldipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Halothane is combined with Nitrazepam.]
[C08CA08, nitrendipine, Halothane may decrease the antihypertensive activities of Nitrendipine.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Halothane.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Halothane.]
[N04BC05, pramipexole, Halothane may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Halothane may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Halothane is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Halothane is combined with Nomifensine.]
[C01CA03, norepinephrine, Halothane may increase the arrhythmogenic activities of Norepinephrine.]
[C02KX01, bosentan, The metabolism of Halothane can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, Halothane may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.]
[R05DA07, noscapine, The metabolism of Halothane can be decreased when combined with Noscapine.]
[G02CA02, nylidrin, The risk or severity of hypertension can be increased when Halothane is combined with Nylidrin.]
[L04AC04, rilonacept, The metabolism of Halothane can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Halothane can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Halothane is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Halothane is combined with Opium.]
[R03CB03, metaproterenol, The risk or severity of hypertension can be increased when Orciprenaline is combined with Halothane.]
[G04CA02, tamsulosin, The risk or severity of adverse effects can be increased when Tamsulosin is combined with Halothane.]
[A14AA08, oxandrolone, The metabolism of Halothane can be decreased when combined with Oxandrolone.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Halothane.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Halothane is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Halothane.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Halothane is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Oxymetazoline is combined with Halothane.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Halothane is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Halothane is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Halothane is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Halothane may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Halothane is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Halothane.]
[M03AC01, pancuronium, Halothane may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Papaverine is combined with Halothane.]
[N05CC05, paraldehyde, Halothane may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Halothane is combined with Pargyline.]
[G04BD11, fesoterodine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Halothane is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Halothane is combined with Penfluridol.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Halothane.]
[N05CA01, pentobarbital, The metabolism of Halothane can be increased when combined with Pentobarbital.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Halothane is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Halothane is combined with Pergolide.]
[C08EX02, perhexiline, The metabolism of Halothane can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Halothane.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Halothane.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Halothane is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Halothane is combined with Phenelzine.]
[N03AA02, phenobarbital, The metabolism of Phenobarbital can be decreased when combined with Halothane.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Halothane is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, Halothane may decrease the antihypertensive activities of Phenoxybenzamine.]
[B01AA04, phenprocoumon, The metabolism of Halothane can be decreased when combined with Phenprocoumon.]
[A08AA01, phentermine, The risk or severity of hypertension can be increased when Phentermine is combined with Halothane.]
[V03AB36, phentolamine, Halothane may decrease the antihypertensive activities of Phentolamine.]
[M02AA01, phenylbutazone, The metabolism of Halothane can be decreased when combined with Phenylbutazone.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Phenylephrine is combined with Halothane.]
[R01BA01, phenylpropanolamine, The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Halothane.]
[N03AB02, phenytoin, The serum concentration of Phenytoin can be increased when it is combined with Halothane.]
[L04AB06, golimumab, The metabolism of Halothane can be increased when combined with Golimumab.]
[C08CX01, mibefradil, Halothane may decrease the antihypertensive activities of Mibefradil.]
[S01EB01, pilocarpine, The metabolism of Halothane can be decreased when combined with Pilocarpine.]
[N05AG02, pimozide, The risk or severity of adverse effects can be increased when Pimozide is combined with Halothane.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Halothane.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Halothane is combined with Pipotiazine.]
[C09CA02, eprosartan, Halothane may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Halothane is combined with Piritramide.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Piroxicam is combined with Halothane.]
[N02CX01, pizotyline, Halothane may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Halothane can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, Halothane may decrease the antihypertensive activities of Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Halothane is combined with Proxibarbal.]
[A10BG02, rosiglitazone, The metabolism of Halothane can be decreased when combined with Rosiglitazone.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Halothane.]
[L04AC08, canakinumab, The metabolism of Halothane can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Halothane may decrease the antihypertensive activities of Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Halothane can be increased when it is combined with Ritonavir.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Halothane.]
[C07AB01, practolol, Halothane may decrease the antihypertensive activities of Practolol.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Halothane is combined with Prazepam.]
[C02CA01, prazosin, Halothane may decrease the antihypertensive activities of Prazosin.]
[H02AB07, prednisone, The metabolism of Halothane can be increased when combined with Prednisone.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Halothane.]
[N03AA03, primidone, Primidone may increase the hypotensive activities of Halothane.]
[M04AB01, probenecid, The metabolism of Halothane can be decreased when combined with Probenecid.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Halothane is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Halothane is combined with Procarbazine.]
[C10AB05, fenofibrate, The metabolism of Halothane can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Halothane.]
[N04AA04, procyclidine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Halothane can be increased when combined with Progesterone.]
[N05AA03, promazine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The risk or severity of hypertension can be increased when Halothane is combined with Propafenone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Halothane is combined with Propanidid.]
[A03AB05, propantheline, Halothane may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Halothane is combined with Periciazine.]
[N05CM06, propiomazine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Halothane.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Halothane.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Halothane.]
[C07AA05, propranolol, Halothane may decrease the antihypertensive activities of Propranolol.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Halothane.]
[B01AC09, epoprostenol, Halothane may decrease the antihypertensive activities of Epoprostenol.]
[R03DC03, montelukast, The metabolism of Halothane can be decreased when combined with Montelukast.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Halothane.]
[R01BA02, pseudoephedrine, The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Halothane.]
[N05AX12, aripiprazole, Halothane may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[A03AB15, diphemanil, Halothane may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Halothane may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Halothane.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Halothane is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Halothane is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Halothane is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Halothane is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Halothane is combined with Mepyramine.]
[C01BA01, quinidine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Quinidine.]
[P01BC01, quinine, The risk or severity of adverse effects can be increased when Quinine is combined with Halothane.]
[C02AA01, rescinnamine, Halothane may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Halothane.]
[J04AB02, rifampin, The metabolism of Halothane can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Halothane is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of hypertension can be increased when Ritodrine is combined with Halothane.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Halothane is combined with Oxitriptan.]
[A16AA02, S-adenosylmethionine, The metabolism of Halothane can be decreased when combined with Ademetionine.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Halothane is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Sulfasalazine is combined with Halothane.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Salicylic acid is combined with Halothane.]
[S01FA02, scopolamine, Halothane may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Halothane.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Halothane is combined with Selegiline.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Halothane is combined with Obinutuzumab.]
[C07AA07, sotalol, The risk or severity of adverse effects can be increased when Sotalol is combined with Halothane.]
[C03DA01, spironolactone, The risk or severity of adverse effects can be increased when Spironolactone is combined with Halothane.]
[C01DA14, isosorbide mononitrate, The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Halothane.]
[H02CA04, levoketoconazole, The metabolism of Halothane can be decreased when combined with Levoketoconazole.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Halothane is combined with Tiaprofenic acid.]
[C03CC01, ethacrynic acid, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Halothane.]
[R03BB01, ipratropium bromide, Halothane may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
